Liver Cirrhosis Patients Homozygous for MTHFR C677T Develop Portal Vein Thrombosis 8 Years Earlier Than Wild Type

[1]  C. Samama,et al.  A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing , 2022, Research and practice in thrombosis and haemostasis.

[2]  Ge Guan,et al.  A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis , 2022, Annals of medicine.

[3]  Sophia Seen.  Chronic liver disease and oxidative stress – a narrative review , 2021, Expert review of gastroenterology & hepatology.

[4]  M. Margaglione,et al.  Homozygous methylentetrahydrofolate reductase C667T genotype anticipates age at venous thromboembolism by one decade , 2021, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  D. Valla,et al.  Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study , 2020, European journal of gastroenterology & hepatology.

[6]  S. Resino,et al.  MTHFR rs1801133 Polymorphism Is Associated With Liver Fibrosis Progression in Chronic Hepatitis C: A Retrospective Study , 2020, Frontiers in Medicine.

[7]  Jiahuai Han,et al.  Bacterial Endotoxin Activates the Coagulation Cascade through Gasdermin D-Dependent Phosphatidylserine Exposure. , 2019, Immunity.

[8]  Z. Kadry,et al.  Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  Z. Kadry,et al.  Inherited thrombophilia and portal vein thrombosis in cirrhosis: A systematic review and meta‐analysis , 2019, Research and practice in thrombosis and haemostasis.

[10]  Yinan Wei,et al.  Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis. , 2019, Immunity.

[11]  B. Zarić,et al.  Homocysteine and Hyperhomocysteinaemia. , 2019, Current medicinal chemistry.

[12]  G. Corazza,et al.  Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis , 2019, Hepatology communications.

[13]  Zhaoxi Sun,et al.  Thermodynamics of helix formation in small peptides of varying length in vacuo, in implicit solvent, and in explicit solvent , 2018, Journal of Molecular Modeling.

[14]  Qinghua Zeng,et al.  Correlations between methylenetetrahydrofolate reductase gene polymorphisms and venous thromboembolism: A meta-analysis of 99 genetic association studies , 2018, European journal of preventive cardiology.

[15]  S. Sarin,et al.  Decreased protein C function predicts mortality in patients with cirrhosis , 2018, International journal of laboratory hematology.

[16]  Wei Chen,et al.  An evidence-based approach to globally assess the covariate-dependent effect of the MTHFR single nucleotide polymorphism rs1801133 on blood homocysteine: a systematic review and meta-analysis. , 2018, The American journal of clinical nutrition.

[17]  J. Qian,et al.  Allosteric control of human cystathionine β-synthase activity by a redox active disulfide bond , 2018, The Journal of Biological Chemistry.

[18]  Huirong Liu,et al.  Nitration‐mediated deficiency of cystathionine &bgr;‐synthase activity accelerates the progression of hyperhomocysteinemia , 2017, Free radical biology & medicine.

[19]  D. Christodoulou,et al.  Haemostatic balance in patients with end-stage cirrhosis: low protein C is the predominant coagulant protein deficiency. , 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[20]  G. Carvalhal,et al.  Glutamine prevents oxidative stress in a model of portal hypertension , 2017, World journal of gastroenterology.

[21]  Georg Heinze,et al.  Five myths about variable selection , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[22]  F. Gentile,et al.  Nitric oxide metabolites, nitrative stress, and paraoxonase activity in hepatopulmonary syndrome , 2016, Scandinavian journal of gastroenterology.

[23]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[24]  D. Fan,et al.  Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd–Chiari syndrome and portal vein thrombosis: A systematic review and meta‐analysis of observational studies , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  H. Blom,et al.  Folic acid supplementation does not reduce intracellular homocysteine, and may disturb intracellular one-carbon metabolism , 2013, Clinical chemistry and laboratory medicine.

[26]  C. Curry,et al.  ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing , 2013, Genetics in Medicine.

[27]  S. Bessa,et al.  Portal vein thrombosis in Egyptian patients with liver cirrhosis: Role of methylenetetrahydrofolate reductase C677T gene mutation , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[28]  Ning Yang,et al.  Protein C and D‐dimer are related to portal vein thrombosis in patients with liver cirrhosis , 2010, Journal of gastroenterology and hepatology.

[29]  E. Lonn,et al.  Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism , 2007, Annals of Internal Medicine.

[30]  M. Margaglione,et al.  Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation , 2006, Thrombosis and Haemostasis.

[31]  S. Tyagi,et al.  Mechanisms of homocysteine-induced oxidative stress. , 2005, American journal of physiology. Heart and circulatory physiology.

[32]  A. Cimmino,et al.  Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients , 2005, Hepatology.

[33]  H. Blom,et al.  Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. , 2004, Blood.

[34]  T. Orfeo,et al.  Homocysteine Inhibits Inactivation of Factor Va by Activated Protein C* , 2001, The Journal of Biological Chemistry.

[35]  S. Olliff,et al.  Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. , 2000, Transplantation.

[36]  J. Morrow,et al.  Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[37]  P. Mannucci,et al.  Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism: relationships with plasma homocysteine levels. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[38]  J. Sadler,et al.  Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. , 1991, The Journal of clinical investigation.

[39]  C. Schöneich.  Sulfur Radical-Induced Redox Modifications in Proteins: Analysis and Mechanistic Aspects. , 2017, Antioxidants & redox signaling.

[40]  C. Byrne,et al.  Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. , 1998, Blood.

[41]  M. Margaglione,et al.  Thrombophilic Genotypes in Subjects with Idiopathic Antiphospholipid Antibodies – Prevalence and Significance , 1998, Thrombosis and Haemostasis.